Dr. Williams' research focuses on platelet physiology particularly as it relates to acute coronary syndromes and depression. Her laboratory specifically examines platelet aggregation, flow cytometric analysis to measure platelet activation, platelet luminescence as a measure of the platelet release reaction, many Elisa preparations in order to measure platelet function, platelet genotyping to determine the presence of certain platelet polymorphisms, and various other assays to distinguish mechanisms of platelet dysfunction. The goal for her cardiovascular platelet laboratory is to identify the etiology of platelet dysfunction in many disease states and apply methods that may improve this dysfunction that can eventually be translated to therapies for patients with cardiovascular disease. Scientific techniques performed in the lab include: flow cytometric analysis, platelet microparticle identification, and protein immunoprecipitation among other techniques.

The Allan Gelber Lab conducts research on the clinical epidemiology of rheumatic disorders. Our recent studies have explored topics that include the predicting factors of prevalent and incident gout; cardiovascular disease burden and risk in patients with rheumatoid arthritis; autoantibodies in both primary and secondary SjogrenÕs syndrome; and predictors of outcomes in patients with scleroderma. In addition, we have a long-standing interest in the ways in which racial differences affect disease manifestations in relation to rheumatic disorders.

Researchers in the Adam Sapirstein Lab focus on the roles played by phospholipases A2 and their lipid metabolites in brain injury. Using in vivo and in vitro models of stroke and excitotoxicity, the team is examining the roles of the cytosolic, Group V, and Group X PLA2s as well as the function of PLA2s in cerebrovascular regulation. Investigators have discovered that cPLA2 is necessary for the early electrophysiologic changes that happen in hippocampal CA1 neurons after exposure to N-methyl-d-aspartate (NMDA). This finding has critical ramifications in terms of the possible uses of selective cPLA2 inhibitors after acute neurologic injuries.

Dr. Hua's research has centered on the development of novel MRI technologies for in vivo functional and physiological imaging in the brain, and the application of such methods for studies in healthy and diseased brains. These include the development of human and animal MRI methods to measure functional brain activities, cerebral perfusion and oxygen metabolism at high (3 Tesla) and ultra-high (7 Tesla and above) magnetic fields. He is particularly interested in novel MRI approaches to image small blood and lymphatic vessels in the brain. Collaborating with clinical investigators, these techniques have been applied 1) to detect functional, vascular and metabolic abnormalities in the brain in neurodegenerative diseases such as Huntingdon's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD) and mental disorders such as schizophrenia; and 2) to map brain functions and cerebrovascular reactivity for presurgical planning in patients with vascular malformations, brain tumors and epilepsy.

Research in the Jeffrey Dodd-o Lab aims to better understand the contributing factors of lung ischemia/reperfusion injuries and the role these injuries play in the lung dysfunction of patients soon after cardiopulmonary bypass surgery. We have created an ischemia/reperfusion model in a spontaneously breathing mouse that they use with an in situ mouse lung preparation to identify cardiopulmonary interactions that impact reperfusion-related lung injury. We are working to characterize the influence of atrial natriuretic peptide (ANP) on lung microvascular permeability.

The Wang lab focuses on the signals that direct the differentiation of pluripotent stem cells, such as induced-pluripotent stem (iPS) cells, into hematopoietic and cardiovascular cells. Pluripotent stem cells hold great potential for regenerative medicine. Defining the molecular links between differentiation outcomes will provide important information for designing rational methods of stem cell manipulation.

Dr. Bhujwalla’s lab promotes preclinical and clinical multimodal imaging applications to understand and effectively treat cancer. The lab’s work is dedicated to the applications of molecular imaging to understand cancer and the tumor environment. Significant research contributions include 1) developing ‘theranostic agents’ for image-guided targeting of cancer, including effective delivery of siRNA in combination with a prodrug enzyme 2) understanding the role of inflammation and cyclooxygenase-2 (COX-2) in cancer using molecular and functional imaging 3) developing noninvasive imaging techniques to detect COX-2 expressing in tumors 4) understanding the role of hypoxia and choline pathways to reduce the stem-like breast cancer cell burden in tumors 5) using molecular and functional imaging to understand the role of the tumor microenvironment including the extracellular matrix, hypoxia, vascularization, and choline phospholipid metabolism in prostate and breast cancer invasion and metastasis, with the ultimate goal of preventing cancer metastasis and 6) molecular and functional imaging characterization of cancer-induced cachexia to understand the cachexia-cascade and identify novel targets in the treatment of this condition.

Research in the Deborah Schwengel Lab focuses on perioperative care of pediatric patients with obstructive sleep apnea as well as anesthetic care for patients undergoing ethanol embolization of vascular malformations. Our team also explores topics within graduate medical education. In this field, our work has involved evaluating both an educational curriculum and a disaster preparedness curriculum for anesthesiology residents. We also have a long-standing interest in international adoption medicine.

Researchers in the David Thompson Lab examine the outcomes of patients treated in intensive care units (ICUs), patient safety efforts, quality improvement efforts, and multidisciplinary teamwork and safety curriculum development. We're taking part in a study aimed at reducing hospital-acquired infections among cardiovascular surgery patients. Our investigators also participated in a clinical research collaboration that saw an 81 percent reduction in bloodstream infections related to central lines.

I am a primary care doctor and public health researcher committed to improving women’s health and health care across their lives and improving gender and racial equity.

I am an Associate Professor of Medicine in The Johns Hopkins University School of Medicine, Division of General Internal Medicine. My research focuses on identifying strategies to prevent and manage obesity and type 2 diabetes and cardiovascular disease, particularly among women at highest risk due to pregnancy complications. I conduct pragmatic and community-based randomized controlled trials to test high impact and scalable strategies to reduce excessive weight gain in pregnancy, reduce postpartum weight retention and cardiometabolic risk.

I hold several leadership positions, and I am the Director of Research at Johns Hopkins Community Physicians, the Co-Director of the Johns Hopkins Center for Women’s Health, Sex and Gender Research and a Core Faculty Member of the Welch Center for Prevention, Epidemiology and Clinical Research.